Greg Robertson was named to the NIH PReclinical DesIgn and Clinical Translation of TB Regimens (PReDicTR) Consortium.

A collaborative study, including the CSU Mycobacteria Research Laboratories, provides an important new basis for comparing the effectiveness of different tuberculosis treatments and accelerating the development of shorter regimens.

The Consortium for Applied Microbial Metrics led by scientists at the University of Colorado Anschutz Medical Campus, Colorado State University and University of California San Francisco, combines insights from in vitro, animal and human studies to identify better tuberculosis treatments.